“This CFDA clearance is a significant milestone achievement for SpineCraft and further advances our strategy to establish SpineCraft as a true global spine company.” said SpineCraft CEO Wagdy Asaad, MD.
The China spine market has become the second most important after the USA and is projected to be worth over $1 billion by 2019. This is driven by China’s large population, rising standard of living, improving treatment options and growing ageing population; all signal significant room for growth.
To learn more about SpineCraft, click here.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
